ES2959183T3 - Derivados de manosa y su uso en el tratamiento de infecciones bacterianas - Google Patents

Derivados de manosa y su uso en el tratamiento de infecciones bacterianas Download PDF

Info

Publication number
ES2959183T3
ES2959183T3 ES14804252T ES14804252T ES2959183T3 ES 2959183 T3 ES2959183 T3 ES 2959183T3 ES 14804252 T ES14804252 T ES 14804252T ES 14804252 T ES14804252 T ES 14804252T ES 2959183 T3 ES2959183 T3 ES 2959183T3
Authority
ES
Spain
Prior art keywords
group
heterocycle
aryl
optionally substituted
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14804252T
Other languages
English (en)
Spanish (es)
Inventor
James W Janetka
Zhenfu Han
Scott Hultgren
Jerry Pinkner
Corinne Cusumano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St. Louis
Original Assignee
Washington University in St. Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St. Louis filed Critical Washington University in St. Louis
Application granted granted Critical
Publication of ES2959183T3 publication Critical patent/ES2959183T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES14804252T 2013-05-30 2014-05-30 Derivados de manosa y su uso en el tratamiento de infecciones bacterianas Active ES2959183T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361828954P 2013-05-30 2013-05-30
PCT/US2014/040355 WO2014194270A1 (en) 2013-05-30 2014-05-30 Compounds and methods for treating bacterial infections

Publications (1)

Publication Number Publication Date
ES2959183T3 true ES2959183T3 (es) 2024-02-21

Family

ID=51989445

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14804252T Active ES2959183T3 (es) 2013-05-30 2014-05-30 Derivados de manosa y su uso en el tratamiento de infecciones bacterianas

Country Status (9)

Country Link
US (4) US9957289B2 (enExample)
EP (1) EP3003322B1 (enExample)
JP (2) JP6640716B2 (enExample)
CN (2) CN105682665A (enExample)
AU (1) AU2014273962B2 (enExample)
CA (1) CA2913622A1 (enExample)
ES (1) ES2959183T3 (enExample)
HK (1) HK1225649A1 (enExample)
WO (1) WO2014194270A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
WO2012109263A1 (en) 2011-02-07 2012-08-16 The Washington University Mannoside compounds and methods of use thereof
HK1225649A1 (zh) 2013-05-30 2017-09-15 Washington University 用於治疗细菌性感染的化合物和方法
MA42145B1 (fr) 2015-05-20 2020-05-29 Amgen Inc Triazoles agonistes du récepteur apj
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
EP3331893B1 (en) * 2015-08-05 2019-05-22 Enterome Mannose derivatives useful for treating pathologies associated with adherent e. coli
CN108883122A (zh) * 2016-03-11 2018-11-23 菲姆布里昂医疗公司 有用于治疗疾病的c-糖苷化合物
BR112018069147A2 (pt) * 2016-03-23 2019-01-22 Fimbrion Therapeutics Inc composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
EP3541802B1 (en) 2016-11-16 2025-01-01 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
HRP20220223T1 (hr) 2017-01-11 2022-04-29 Alkermes, Inc. Biciklički inhibitori histon deacetilaze
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
WO2019076931A1 (en) 2017-10-16 2019-04-25 Enterome NEW TOOLS FOR EVALUATING THE THERAPEUTIC EFFECTIVENESS OF FIMH BLOCKERS
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
EP3788037A1 (en) 2018-05-01 2021-03-10 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
ES2928634T3 (es) * 2018-07-10 2022-11-21 Glaxosmithkline Ip Dev Ltd Compuestos de C-manósido útiles para el tratamiento de infecciones de las vías urinarias
CN109762034B (zh) * 2019-02-23 2022-04-29 福建医科大学 新型对苯二甲醛缩d-氨基葡萄糖席夫碱的制备方法
US12297223B2 (en) 2019-05-07 2025-05-13 Glaxosmithkline Intellectual Property Development Limited Compounds
US12351597B2 (en) 2019-06-19 2025-07-08 Glaxosmithkline Intellectual Property Development Limited Substituted biphenyl or phenylheteroaryl-mannosides as antagonists of FimH
AU2021229482B2 (en) * 2020-03-02 2026-05-14 Nimesh Patel A pharmaceutical composition and method of treatment using Serratiopeptidase, Mannose or its derivative, and optionally antinfection agents
CN113461753B (zh) * 2020-03-31 2023-05-23 郑计岳 2-炔基甘露糖衍生物及其应用
CN113797212B (zh) * 2020-06-11 2023-12-22 兰州大学 一组含有甘露糖结构的抗菌药物的合成方法及活性研究
US12617813B2 (en) 2020-12-28 2026-05-05 Georgia Tech Research Corporation Glycosylated histone deacetylase inhibitors and methods of making and using the same
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
CN116023273A (zh) * 2023-03-29 2023-04-28 思合基因(北京)生物科技有限公司 一种新型碳糖苷及其制备方法
EP4702975A1 (en) * 2024-09-03 2026-03-04 Biotecnica Di Magagnini Mattia E Malatini Silvia Snc Stp Nutraceutical composition for the treatment of cystitis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122602A (en) 1989-02-13 1992-06-16 Miles Inc. Chromogenic merocyanine enzyme substrates
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
EP0730601B1 (en) 1993-11-18 2004-07-14 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
AU7470300A (en) 1999-08-11 2001-03-05 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
WO2001095876A1 (en) 2000-06-09 2001-12-20 Baylor College Of Medicine The combination of antimicrobial agents and bacterial interference to coat medical devices
WO2005033059A1 (es) 2003-10-08 2005-04-14 Innovaprotean, S.L. Compuestos útiles para el tratamiento de enfermedades asociadas a la formación de fibrilas amiloides
EP1755619A2 (en) 2004-03-23 2007-02-28 VIB vzw Anti-adhesive compounds to prevent and treat bacterial infections
SE528382C2 (sv) 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
FR2876798A1 (fr) 2004-10-14 2006-04-21 Univ Clermont Auvergne Diagnostic et traitement de la maladie de crohn
EP2490530A4 (en) 2009-10-22 2014-01-22 Univ Washington COMPOUNDS AND METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS
WO2012109263A1 (en) * 2011-02-07 2012-08-16 The Washington University Mannoside compounds and methods of use thereof
SG181115A1 (en) * 2009-12-14 2012-07-30 Univ Basel Mannose derivatives as antagonists of bacterial adhesion
WO2012164074A1 (en) * 2011-06-03 2012-12-06 University Of Basel Mannose phosphate derivatives as antagonists of bacterial adhesion
HK1225649A1 (zh) 2013-05-30 2017-09-15 Washington University 用於治疗细菌性感染的化合物和方法

Also Published As

Publication number Publication date
US20210122776A1 (en) 2021-04-29
US20180194792A1 (en) 2018-07-12
CN105682665A (zh) 2016-06-15
EP3003322A1 (en) 2016-04-13
WO2014194270A1 (en) 2014-12-04
JP6640716B2 (ja) 2020-02-05
JP2016520618A (ja) 2016-07-14
HK1225649A1 (zh) 2017-09-15
AU2014273962A1 (en) 2015-12-17
CA2913622A1 (en) 2014-12-04
US9957289B2 (en) 2018-05-01
EP3003322B1 (en) 2023-09-13
EP3003322A4 (en) 2017-01-25
US20160145289A1 (en) 2016-05-26
HK1223546A1 (en) 2017-08-04
AU2014273962B2 (en) 2019-07-25
JP2020073543A (ja) 2020-05-14
CN111423479A (zh) 2020-07-17
US20230033327A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
US20230033327A1 (en) Compounds and methods for treating bacterial infections
US10273260B2 (en) Compounds and methods for treating bacterial infections
EP3492483A1 (en) Compounds and methods for treating bacterial infections
US12030879B2 (en) Sulfonyl acetamides as NLRP3 inhibitors
RU2667060C2 (ru) Производные маннозы для лечения бактериальных инфекций
JP7483820B2 (ja) 新規化合物
RU2678327C2 (ru) Производные маннозы для лечения бактериальных инфекций
EA022562B1 (ru) ПИРАНО[3,2-d][1,3]ТИАЗОЛ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОЗИДАЗЫ
US20130261077A1 (en) Mannose derivatives for treating bacterial infections
HK40034028A (en) Compounds and methods for treating bacterial infections
HK1223546B (en) Mannose derivatives and their use in the treatment of bacterial infections
CN113795487B (zh) 新的化合物
RU2575477C2 (ru) Соединения для лечения заболеваний, связанных с clostridium difficile
EA040307B1 (ru) Модуляторы nlrp3
NZ711932B2 (en) Mannose derivatives for treating bacterial infections